Your session is about to expire
← Back to Search
Deucravacitinib for Psoriasis (ARTISTYK Trial)
ARTISTYK Trial Summary
This trial studies how a drug can help improve quality of life for people with psoriasis.
ARTISTYK Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowARTISTYK Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ARTISTYK Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My doctor thinks I should get light or drug treatment.I have had stable plaque psoriasis for over 6 months without major changes.I have moderate-to-severe plaque psoriasis.Your dermatology life quality index score is higher than 5 at the screening visit and day 1.At least 3% of my skin is affected by my condition.My psoriasis is not plaque type but another form like guttate or pustular.
- Group 1: Deucravacitinib
- Group 2: Placebo then Deucravacitinib
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many sites are currently executing this research trial?
"Arkansas Research Trials, Inc. in North Little Rock and Bakersfield Dermatology Skin cancer Med.Group in Bakersfield are two of the 28 locations currently recruiting patients for this medical trial; Integrative Skin Science and Research in Sacramento is yet another participating site."
Are there any unoccupied slots in this investigation for participants?
"This particular trial is not accepting any new patients, as indicated by the clinicaltrials.gov listing which was last updated on January 26th 2023. However, there are 163 active studies that people can join at this time."
Could you discuss the degree of safety associated with Deucravacitinib?
"There is an abundance of evidence suggesting Deucravacitinib's safety, which earns it a 3 rating on our scale. This drug has reached approval status in the Phase 4 trial process."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger